Literature DB >> 6125725

Repeated suppression of Creutzfeldt-Jakob disease with vidarabine.

T W Furlow, R J Whitley, F J Wilmes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6125725     DOI： 10.1016/s0140-6736(82)90652-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

Review 2.  Prions: Beyond a Single Protein.

Authors:  Alvin S Das; Wen-Quan Zou
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 3.  Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: implications for physicians.

Authors:  C MacKnight; K Rockwood
Journal:  CMAJ       Date:  1996-09-01       Impact factor: 8.262

Review 4.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

5.  Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.

Authors:  John Collinge; Michele Gorham; Fleur Hudson; Angus Kennedy; Geraldine Keogh; Suvankar Pal; Martin Rossor; Peter Rudge; Durre Siddique; Moira Spyer; Dafydd Thomas; Sarah Walker; Tom Webb; Steve Wroe; Janet Darbyshire
Journal:  Lancet Neurol       Date:  2009-03-09       Impact factor: 44.182

Review 6.  Prions and related neurological diseases.

Authors:  M Pocchiari
Journal:  Mol Aspects Med       Date:  1994

7.  Hampering the early aggregation of PrP-E200K protein by charge-based inhibitors: a computational study.

Authors:  Mariangela Agamennone; Loriano Storchi; Alessandro Marrone; Roberto Paciotti
Journal:  J Comput Aided Mol Des       Date:  2021-06-10       Impact factor: 3.686
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.